{"id":10,"date":"2019-06-14T11:57:25","date_gmt":"2019-06-14T11:57:25","guid":{"rendered":"https:\/\/porphyria.network\/IPPN\/?page_id=10"},"modified":"2024-01-14T17:12:04","modified_gmt":"2024-01-14T16:12:04","slug":"publications","status":"publish","type":"page","link":"https:\/\/porphyria.network\/IPPN\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"[vc_row][vc_column][vc_column_text css=&#8221;.vc_custom_1705248718591{margin-left: 10px !important;}&#8221;]\n<h2>Publications<\/h2>\n\n\n<h3>Peer-reviewed papers:<\/h3>\n\n\n<div class=\"wp-container-1 wp-block-group\"><div class=\"wp-block-group__inner-container\"> 1. Barman-Aks\u00f6zen, J., Andreoletti, M., &amp; Blasimme, A. (2023). Current trials in erythropoietic<br \/>protoporphyria: are placebo controls ethical?.\u00a0<em>Orphanet journal of rare diseases<\/em>,\u00a0<em>18<\/em>(1), 325.<br \/><a href=\"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02941-w\">https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02941-w<\/a> \n<p> 2. Barman-Aks\u00f6zen, J., Minder, A. E., Granata, F., Pettersson, M., Dechant, C., Aks\u00f6zen, M. H., &amp; Falchetto,<br \/>R. (2023). Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-<br \/>Initiated EQ-5D Feasibility Study.\u00a0<em>International journal of environmental research and public health<\/em>,\u00a0<em>20<\/em>(7),<br \/>5296.\u00a0<a href=\"https:\/\/doi.org\/10.3390\/ijerph20075296\">https:\/\/doi.org\/10.3390\/ijerph20075296<\/a><\/p>\n\n<p> 3. Barman-Aks\u00f6zen,\u00a0Granata,\u00a0Aks\u00f6zen,\u00a0\u00a0Dechant\u00a0&amp;\u00a0\u00a0Falchetto\u00a0(2022)\u00a0\u2018\u2026\u00a0they\u00a0had\u00a0interpreted\u00a0\u201cdisability\u201d as<br \/>referring to a patently visible disability\u2019: experience of a patient group with NICE,\u00a0Disability &amp;<br \/>Society,\u00a037:7,\u00a01239-1245. <a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09687599.2022.2060804\">https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09687599.2022.2060804<\/a><\/p>\n\n<p> 4. Whitty, J. A., de Bekker-Grob, E. W., Cook, N. S., Terris-Prestholt, F., Drummond, M., Falchetto, R., &amp;<br \/>Hillege, H. L. (2020). Patient Preferences in the Medical Product Lifecycle.\u00a0<em>The patient<\/em>,\u00a0<em>13<\/em>(1), 7\u201310.<br \/><a href=\"https:\/\/doi.org\/10.1007\/s40271-019-00400-y\">https:\/\/doi.org\/10.1007\/s40271-019-00400-y<\/a><\/p>\n\n<p> 5.\u00a0Falchetto R. (2020). The Patient Perspective: A Matter of Minutes.\u00a0<em>The patient<\/em>,\u00a0<em>13<\/em>(1), 1\u20136.<br \/><a href=\"https:\/\/doi.org\/10.1007\/s40271-019-00399-2\">https:\/\/doi.org\/10.1007\/s40271-019-00399-2<\/a><\/p>\n\n<p> 6.\u00a0Barman-Aks\u00f6zen J. Patient empowerment and access to medicines: Insights from a scientist-patient<br \/>suffering from erythropoietic protoporphyria.\u00a0<em>Medicine Access @ Point of Care<\/em>. 2019;3.<br \/><a href=\"https:\/\/journals.sagepub.com\/doi\/10.1177\/2399202619865167\">https:\/\/journals.sagepub.com\/doi\/10.1177\/2399202619865167<\/a><\/p>\n<p>&nbsp;<\/p>\n\n<\/div><\/div>\n\n\n<h3>Correspondence and letters:<\/h3>\n\n\n<div class=\"wp-container-2 wp-block-group\"><div class=\"wp-block-group__inner-container\"> 1. Granata, F., Dechant, C., &amp; Falchetto, R. (2023). Dersimelagon in Erythropoietic Protoporphyrias.\u00a0<em>The <\/em><br \/><em>New England journal of medicine<\/em>,\u00a0<em>388<\/em>(26), 2491\u20132492.\u00a0<a href=\"https:\/\/doi.org\/10.1056\/NEJMc2305601\">https:\/\/doi.org\/10.1056\/NEJMc2305601<\/a> \n<p> 2. Barman-Aks\u00f6zen J. (2022). Are payors ready for transparent prices yet?.\u00a0<em>The Lancet regional health. <\/em><br \/><em>Europe<\/em>,\u00a0<em>19<\/em>, 100444.\u00a0<a href=\"https:\/\/doi.org\/10.1016\/j.lanepe.2022.100444\">https:\/\/doi.org\/10.1016\/j.lanepe.2022.100444<\/a><\/p>\n<p>&nbsp;<\/p>\n\n<\/div><\/div>\n\n\n<h3>Rapid Responses:<\/h3>\n\n<p> 1. Barman-Aks\u00f6zen, Hauke, Falchetto (2023): A rare disease patient perspective on the proposed changes<br \/>of orphan drug regulation. <a href=\"https:\/\/www.bmj.com\/content\/381\/bmj-2022-072796\/rr\">https:\/\/www.bmj.com\/content\/381\/bmj-2022-072796\/rr<\/a><\/p>\n\n<p> 2. Barman-Aks\u00f6zen, Falchetto (2023) We have already lost our trust in NICE \u2013 Our real-life case.<br \/><a href=\"https:\/\/www.bmj.com\/content\/383\/bmj.p2571\/rr-3\">https:\/\/www.bmj.com\/content\/383\/bmj.p2571\/rr-3<\/a><\/p>\n[\/vc_column_text][\/vc_column][\/vc_row]\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text css=&#8221;.vc_custom_1705248718591{margin-left: 10px !important;}&#8221;] Publications Peer-reviewed papers: 1. Barman-Aks\u00f6zen, J., Andreoletti, M., &amp; Blasimme, A. (2023). Current trials in erythropoieticprotoporphyria: are placebo controls ethical?.\u00a0Orphanet journal of rare diseases,\u00a018(1), 325.https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02941-w 2. Barman-Aks\u00f6zen, J., Minder, A. E., Granata, F., Pettersson, M., Dechant, C., Aks\u00f6zen, M. H., &amp; Falchetto,R. (2023). Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other&hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Publications - International Porphyria Patient Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/porphyria.network\/IPPN\/publications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publications - International Porphyria Patient Network\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_column_text css=&#8221;.vc_custom_1705248718591{margin-left: 10px !important;}&#8221;] Publications Peer-reviewed papers: 1. Barman-Aks\u00f6zen, J., Andreoletti, M., &amp; Blasimme, A. (2023). Current trials in erythropoieticprotoporphyria: are placebo controls ethical?.\u00a0Orphanet journal of rare diseases,\u00a018(1), 325.https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02941-w 2. Barman-Aks\u00f6zen, J., Minder, A. E., Granata, F., Pettersson, M., Dechant, C., Aks\u00f6zen, M. H., &amp; Falchetto,R. (2023). Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/porphyria.network\/IPPN\/publications\/\" \/>\n<meta property=\"og:site_name\" content=\"International Porphyria Patient Network\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-14T16:12:04+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/publications\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/publications\/\",\"name\":\"Publications - International Porphyria Patient Network\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\"},\"datePublished\":\"2019-06-14T11:57:25+00:00\",\"dateModified\":\"2024-01-14T16:12:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/publications\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/porphyria.network\/IPPN\/publications\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/publications\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/porphyria.network\/IPPN\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"name\":\"International Porphyria Patient Network\",\"description\":\"Welcome to the International Porphyria Patient Network\",\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\",\"name\":\"International Porphyria Patient Network\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"contentUrl\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"width\":671,\"height\":630,\"caption\":\"International Porphyria Patient Network\"},\"image\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publications - International Porphyria Patient Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/porphyria.network\/IPPN\/publications\/","og_locale":"en_US","og_type":"article","og_title":"Publications - International Porphyria Patient Network","og_description":"[vc_row][vc_column][vc_column_text css=&#8221;.vc_custom_1705248718591{margin-left: 10px !important;}&#8221;] Publications Peer-reviewed papers: 1. Barman-Aks\u00f6zen, J., Andreoletti, M., &amp; Blasimme, A. (2023). Current trials in erythropoieticprotoporphyria: are placebo controls ethical?.\u00a0Orphanet journal of rare diseases,\u00a018(1), 325.https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02941-w 2. Barman-Aks\u00f6zen, J., Minder, A. E., Granata, F., Pettersson, M., Dechant, C., Aks\u00f6zen, M. H., &amp; Falchetto,R. (2023). Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other&hellip;","og_url":"https:\/\/porphyria.network\/IPPN\/publications\/","og_site_name":"International Porphyria Patient Network","article_modified_time":"2024-01-14T16:12:04+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/porphyria.network\/IPPN\/publications\/","url":"https:\/\/porphyria.network\/IPPN\/publications\/","name":"Publications - International Porphyria Patient Network","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/#website"},"datePublished":"2019-06-14T11:57:25+00:00","dateModified":"2024-01-14T16:12:04+00:00","breadcrumb":{"@id":"https:\/\/porphyria.network\/IPPN\/publications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/porphyria.network\/IPPN\/publications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/porphyria.network\/IPPN\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/porphyria.network\/IPPN\/"},{"@type":"ListItem","position":2,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/porphyria.network\/IPPN\/#website","url":"https:\/\/porphyria.network\/IPPN\/","name":"International Porphyria Patient Network","description":"Welcome to the International Porphyria Patient Network","publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/porphyria.network\/IPPN\/#organization","name":"International Porphyria Patient Network","url":"https:\/\/porphyria.network\/IPPN\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/","url":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","contentUrl":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","width":671,"height":630,"caption":"International Porphyria Patient Network"},"image":{"@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/pages\/10"}],"collection":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/comments?post=10"}],"version-history":[{"count":15,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/pages\/10\/revisions"}],"predecessor-version":[{"id":531,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/pages\/10\/revisions\/531"}],"wp:attachment":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/media?parent=10"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}